Kevin Lee Sells 3,212 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee sold 3,212 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the sale, the chief executive officer now owns 380,864 shares in the company, valued at approximately $8,478,032.64. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Bicycle Therapeutics Stock Up 6.3 %

BCYC opened at $23.60 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. Bicycle Therapeutics plc has a 12 month low of $12.54 and a 12 month high of $28.20. The stock has a market capitalization of $1.01 billion, a P/E ratio of -5.30 and a beta of 0.89. The business has a 50 day simple moving average of $23.36 and a 200-day simple moving average of $22.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Tuesday, August 6th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.33. Bicycle Therapeutics had a negative return on equity of 32.80% and a negative net margin of 417.88%. The company had revenue of $9.36 million during the quarter, compared to the consensus estimate of $6.13 million. The company’s revenue for the quarter was down 17.9% on a year-over-year basis. On average, equities analysts anticipate that Bicycle Therapeutics plc will post -3.17 earnings per share for the current fiscal year.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. purchased a new position in Bicycle Therapeutics in the fourth quarter valued at about $137,000. China Universal Asset Management Co. Ltd. increased its stake in Bicycle Therapeutics by 71.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,859 shares of the company’s stock valued at $171,000 after purchasing an additional 2,858 shares in the last quarter. XTX Topco Ltd acquired a new position in Bicycle Therapeutics during the second quarter worth $206,000. PDS Planning Inc purchased a new stake in Bicycle Therapeutics during the first quarter worth $210,000. Finally, Natixis Advisors LLC acquired a new stake in Bicycle Therapeutics in the second quarter valued at $261,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Bicycle Therapeutics in a report on Monday, September 16th. Oppenheimer restated an “outperform” rating and issued a $48.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, September 16th. JMP Securities reissued a “market outperform” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday, September 16th. Finally, B. Riley downgraded Bicycle Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $33.00 to $28.00 in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.56.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.